Modification of topoisomerases in mammospheres derived from breast cancer cell line: clinical implications for combined treatments with tyrosine kinase inhibitors

Abstract

BackgroundAccumulating evidences suggest that tumors are driven by a small population of cells, termed “cancer stem cells” (CSCs), which may be resistant to current therapeutic approaches. In breast carcinoma, the CSCs have been identified as a CD44+/CD24− cell population. These rare cells are able to grow as non-adherent sphere-like structures, termed “mammospheres”, which enables their isolation and expansion in culture. To design efficient strategies for the complete eradication of CSCs, it is important to identify enzymes and proteins that are known as anti-cancer targets, and differ in their properties from those present in the none CSCs. Here we investigated the activity and expression of type I and type II DNA topoisomerases (topo I and topo II) in CSCs and their response to anti-topoisomerase inhibitors.MethodsMCF7 breast cancer cells, PC3 prostate cancer cells and 4 T1-Luc-Oct3/4pG mouse mammary carcinoma cells were grown on low-attachment dishes in specific medium and allowed to form spheres. Enrichment of CSC population was verified by immunostaining, flow cytometry or fluorescent microscopy imaging. Nuclear protein extracts were prepared and topoisomerases activity and protein levels were determined. Cell viability was examined by the MTT and Neutral Red assays.ResultsUnlike the adherent MCF7 cell line, topo I activity is decreased and topo II activity is increased in the CSCs. However, the relative levels of the enzyme proteins were similar in both mammospheres and adherent cells. Topo I activity in mammospheres is regulated, at least in part, by PARP-1, as observed by the recovery of topo I activity after treatment with PARP-1 inhibitor 3-Aminobenzamide. Mammosphere-derived cells show reduced sensitivity to topo I inhibitor, camptothecin, and increased sensitivity to topo II inhibitor etoposide. Intact mammospheres show increased resistance to both drugs. A combined treatment of intact mammospheres with either CPT and gefitinib, or etoposide and erlotinib, increased the anti-cancer effect of both drugs.ConclusionsThe data of this study suggest that the understanding of biological behavior of essential enzymes such as topoisomerases, in CSCs’ progression and early stages of tumor development, is important for developing new strategies for cancer treatment as well as new therapies for advanced disease.Electronic supplementary materialThe online version of this article (doi:10.1186/1471-2407-14-910) contains supplementary material, which is available to authorized users.

Spheres from cervical cancer cells display stemness and cancer drug resistance

“…At present, the sorting methods of CSCs include flow cytometry based on special cell surface markers, the side population cell sorting technique, tumor sphere culturing and the ALDEFLUOR™ assay (6)(7)(8)(9). Previous studies have identified the CSCs from colon, breast and glioblastoma cancer, as well as other cancer cell lines, using the sphere culturing method (10)(11)(12). Tumor cell sphere culturing may be a convenient method for generating cancer stem-like cells to be used in the research of malignant behavior.…”

New 3‐alkylpyridine marine alkaloid analogues as promising antitumor agents against the CD44+/high/CD24−/low subset of triple‐negative breast cancer cell line

“…Located at the top of the tumor hierarchy, CSC can self‐renew and generate non‐CSC progeny that form the tumor bulk (differentiated progeny) . Additionally, CSC has been suggested to account for tumor growth, progression, metastatic capacity, and therapy resistance . Our results showed that the compounds assessed acted in different ways in monolayer and tumorsphere models.…”

Gefitinib enhances sensitivity of endometrial cancer cells to progestin therapy via dual-specificity phosphatase 1

“…MPA and Gefitinib are effective drugs in breast and endometrial cancer therapy [ 12 , 26 ]. Moreover, Gefitinib is an effective drug in therapy for prostate, gastric, colorectal and non-small cell lung cancers [ 27 – 30 ]. Our data demonstrates that Gefitinib enhances anti-tumor properties of MPA via DUSP1 in EC cells, both in-vitro and in-vivo .…”